MEDICLIN AG
MED
ISIN DE0006595101 / Valor 1158721
MEDICLIN AG
UMushroom community rating:
About company
MEDICLIN AG is a healthcare provider based in Germany, specializing in a comprehensive range of medical services. The company operates across the healthcare spectrum, focusing on acute care, rehabilitation (post-acute care), and inpatient nursing care services. With a network of facilities throughout Germany, MEDICLIN is positioned to offer a continuum of care to patients, encompassing immediate medical treatment, recovery, and long-term care. This integrated approach ensures that patients receive tailored healthcare services designed to meet their individual needs, from initial diagnosis through to rehabilitation and beyond. MEDICLIN's commitment to offering professional medical services is central to its operations, aiming to provide high-quality care across its various healthcare domains.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (05.05.2026):
MEDICLIN AG — interim results for the first nine months of 2025 (reporting as of 30 September 2025 / Q3 2025): the Group delivered solid top‑line and profit growth driven by higher rehabilitation revenues and an acquisition. Sales rose to €586.9m (+5.1% y/y), EBITDA improved to €88.0m (margin 15.0%), EBIT to €48.9m and earnings per share to €0.53. Cash flow from operations strengthened to €75.6m and the balance sheet shows a stronger equity position (equity €248.1m, equity ratio 27.2%). Management confirmed full‑year 2025 guidance.
Sales and profitability
Group sales: €586.9m (+5.1% vs 9M 2024). EBITDA €87.98m (9M 2024: €71.62m), EBITDA margin 15.0% (vs 12.8%). EBIT €48.91m (vs €34.47m). Total consolidated result €25.32m; EPS €0.53 (9M 2024: €0.31).
Cash, liquidity and investment
Cash and cash equivalents €117.3m at 30.09.2025 (includes €15.9m pandemic support likely repayable and €18.3m in subsidies for a new clinic). Cash flow from operating activities €75.6m (9M 2024: €59.5m). Gross capital expenditure €36.6m (9M 2024: €31.4m).
Net financial position and balance sheet
Net financial debt (adjusted) was negative at €‑21.3m (improved from €‑9.1m at 31.12.2024). Equity rose to €248.1m; equity ratio 27.2% (31.12.2024: 24.6%). Financial liabilities to banks €65.4m; lease liabilities remain significant under IFRS 16.
Segment performance
Post‑acute segment drove growth: sales €394.6m (+9.3%) and operating result €47.6m (+25.4%). Acute segment sales fell to €169.8m (‑3.2%) mainly due to the sale of the former Herzzentrum Coswig; acute operating result improved to €0.7m. Nursing care slightly up in sales but small negative operating result (€‑0.4m). Service segment profit €1.0m.
Costs and staffing
Staff costs increased to €369.4m (+4.5% y/y), largely from the Reha‑Klinik am Sendesaal acquisition, new operations (MEDICLIN CAMPUS Wertheim) and wage increases. Raw materials and consumables decreased modestly to €94.4m.
Outlook
Management reaffirmed the 2025 guidance: Group sales growth between 2.0%–5.0% and Group EBIT between €53.0m and €64.0m, assuming broadly stable conditions.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
230 M
Market cap (USD)
1,301
Daily traded volume (Shares)
2.42 / 2.34
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
